A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Abstract

Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality among women. Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease. Ongoing Phase III monotherapy and Phase Ib/II combination trials evaluating its activity in the setting of platinum resistance are emphasized, which will help define its role in the evolving landscape of ovarian cancer therapy.

• Authors: Kathleen N Moore, Lainie P Martin, David M O'Malley, Ursula A Matulonis, Jason A Konner, Ignace Vergote, Jose F Ponte, Michael J Birrer
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 2 Pg. 123-136 (Jan 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29098867 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• FOLR1 protein, human
• Folate Receptor 1
• Immunoconjugates
• Maytansine
• Platinum
• mirvetuximab soravtansine

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Drug Resistance, Neoplasm (genetics)
• Female
• Folate Receptor 1 (antagonists & inhibitors, immunology)
• Humans
• Immunoconjugates (immunology, therapeutic use)
• Maytansine (analogs & derivatives, therapeutic use)
• Ovarian Neoplasms (drug therapy, genetics, pathology)
• Platinum (adverse effects, therapeutic use)